Rating Change
Barclays analysts initiated coverage on The Chemours Company (NYSE:CC) with a rating of Equal-Weight on October 13, 2026.
new coverageNYSE:CC
Barclays Initiates Coverage on The Chemours Company (CC) with Equal-Weight
Barclays analysts initiated coverage on The Chemours Company (NYSE:CC) with a rating of Equal-Weight on October 13, 2026.
At publication ·
What changed
The Chemours Company (NYSE:CC) · new coverage
- Firm
- Barclays
- Rating
- Equal-Weight
- Price at event
- $13.20
- Market capitalization
- $2.0B
At a glance
Key takeaways
- Barclays initiated Equal-Weight coverage on The Chemours Company on October 13, 2026, indicating a neutral outlook on the stock.
Market Context
The Chemours Company operates in the Basic Materials sector. The stock currently trades at $13.20 with a market capitalization of $2.0B. The stock has gained 2.3% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for The Chemours Company.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for The Chemours Company
Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 13, 2026 | Barclays | Equal-Weight | N/A |
| Oct 05, 2026 | UBS | Neutral | N/A |
| Sep 30, 2026 | Mizuho | Outperform | N/A |
| Aug 13, 2026 | JP Morgan | Neutral | N/A |
| Aug 13, 2026 | BMO Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View CC Stock Page
Frequently Asked Questions
What does the Equal-Weight rating mean for CC?
A rating of Equal-Weight from Barclays reflects the analyst's outlook on The Chemours Company (NYSE:CC). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CC forecast page.